Epitopes required for antibody-dependent enhancement of Ebola virus infection.

We have shown that antibody-dependent enhancement (ADE) of infection with Zaire Ebola virus (ZEBOV) is mediated by interaction of virus-specific antibodies with Fc receptors or complement component C1q and its receptors in vitro. ADE activities of the antisera to the viral glycoprotein (GP) were virus species specific and were primarily correlated with immunoglobulin (Ig) G2a and IgM levels but not with IgG1 levels. Interestingly, compared with ZEBOV, Reston Ebola virus (REBOV) had substantially weaker potential to induce ADE antibodies. Using monoclonal antibodies, we identified ZEBOV-specific ADE epitopes. To confirm epitope specificity, we constructed a chimeric ZEBOV GP, the ADE epitopes of which were replaced with the corresponding regions of REBOV GP. We found that mouse antisera to the chimeric ZEBOV GP showed less potential to induce ADE activity than did mouse antisera to wild-type ZEBOV GP, although they retained neutralizing activity. These data suggest that GP lacking the ADE-inducing epitopes may increase the potential of GP as a vaccine antigen.

[1]  Y. Kawaoka,et al.  Protective efficacy of neutralizing antibodies against Ebola virus infection. , 2007, Vaccine.

[2]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[3]  K. Yoshimatsu,et al.  Antibody-dependent enhancement of hantavirus infection in macrophage cell lines , 2005, Archives of Virology.

[4]  Y. Kawaoka,et al.  Human Macrophage C-Type Lectin Specific for Galactose and N-Acetylgalactosamine Promotes Filovirus Entry , 2004, Journal of Virology.

[5]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[6]  M. Mohamadzadeh,et al.  Ebola virus-like particles protect from lethal Ebola virus infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Y. Kawaoka,et al.  Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications , 2003, Reviews in medical virology.

[8]  Y. Kawaoka,et al.  Antibody-Dependent Enhancement of Ebola Virus Infection , 2003, Journal of Virology.

[9]  Shinji Watanabe,et al.  Identification of Protective Epitopes on Ebola Virus Glycoprotein at the Single Amino Acid Level by Using Recombinant Vesicular Stomatitis Viruses , 2003, Journal of Virology.

[10]  Emiko Suzuki,et al.  Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP , 2002, Journal of Virology.

[11]  Y. Kawaoka,et al.  The pathogenesis of Ebola hemorrhagic fever. , 2001, Trends in microbiology.

[12]  Shinji Watanabe,et al.  Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein , 2001, Journal of Virology.

[13]  Shinji Watanabe,et al.  Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. , 2000, Virology.

[14]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[15]  P. Debré,et al.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients , 1999, Nature Medicine.

[16]  L. Klickstein,et al.  C1q-binding proteins and C1q receptors. , 1999, Current opinion in immunology.

[17]  A. Rowe,et al.  Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[18]  J. McCormick,et al.  Experimental filovirus infections. , 1999, Current topics in microbiology and immunology.

[19]  P. Eggleton,et al.  C1q--how many functions? How many receptors? , 1998, Trends in cell biology.

[20]  P. Bates,et al.  Characterization of Ebola Virus Entry by Using Pseudotyped Viruses: Identification of Receptor-Deficient Cell Lines , 1998, Journal of Virology.

[21]  S. Meri.  Complement Fixation Test , 1998 .

[22]  Max Sussman,et al.  Topley and Wilson's Microbiology and Microbial infections , 1998 .

[23]  I. Roitt,et al.  Encyclopedia of immunology , 1998 .

[24]  A. Sanchez,et al.  A system for functional analysis of Ebola virus glycoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Sanchez,et al.  The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Volchkov,et al.  GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. , 1995, Virology.

[27]  P. Jahrling,et al.  Immune serum increases arenavirus replication in monocytes. , 1988, The Journal of general virology.

[28]  A. Allison,et al.  Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection , 1977, The Journal of experimental medicine.